{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T12:06:18Z","timestamp":1784376378870,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To review the efficacy and safety of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea (uUGG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar with the search terms \u201czoliflodacin,\u201d \u201cAZD0914,\u201d and \u201cETX0914.\u201d All relevant English-language articles of studies assessing the efficacy and safety of zoliflodacin for the treatment of uUGG were included. Other resources included abstracts presented at recent conferences, the manufacturer\u2019s website, and prescribing information. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic with a novel mechanism of action and has been shown to be highly active against Neisseria gonorrhoeae, including strains resistant to other antibiotics such as ceftriaxone and azithromycin. It is FDA approved for the treatment of uUGG in adult and pediatric patients aged 12 or older and weighing at least 35\u2005kg and is administered as a one-time oral dose of 3,000\u2005mg. In a large phase 3 trial, zoliflodacin was noninferior to ceftriaxone plus azithromycin for the treatment of uUGG in both men and women and demonstrated a favorable safety and tolerability profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Zoliflodacin is a newly approved antibiotic with a novel mechanism of action that is highly effective for the treatment of uUGG. It is given as a single dose that can be administered orally at the time of diagnosis, thereby avoiding the intramuscular injection necessary with ceftriaxone. It is also effective against gonorrhea strains resistant to other antibiotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag204","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:05:41Z","timestamp":1783065941000},"source":"Crossref","is-referenced-by-count":0,"title":["Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea"],"prefix":"10.1093","author":[{"given":"Spencer H","family":"Durham","sequence":"first","affiliation":[{"name":"Auburn University Harrison College of Pharmacy , Huntsville, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias B","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Gregory School of Pharmacy, Palm Beach Atlantic University , West Palm Beach, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026071807464706600_zxag204-B1","author":"World Health Organization"},{"key":"2026071807464706600_zxag204-B2","volume-title":"Sexually Transmitted Infections Surveillance, 2024 (Provisional)","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"2026071807464706600_zxag204-B3","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2026071807464706600_zxag204-B4","volume-title":"Sexually Transmitted Disease Surveillance 2019","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"2026071807464706600_zxag204-B5","volume-title":"WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance","author":"World Health Organization","year":"2024"},{"key":"2026071807464706600_zxag204-B6","volume-title":"Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): Gonorrhoea Treatment Optimization, 2025 Report","author":"World Health Organization","year":"2025"},{"key":"2026071807464706600_zxag204-B7","author":"Food and Drug Administration"},{"key":"2026071807464706600_zxag204-B8","author":"Nuzolvence (zoliflodacin)"},{"issue":"1","key":"2026071807464706600_zxag204-B9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/ijms27010496","article-title":"Gyrase and topoisomerase IV as antibacterial targets for gepotidacin and zoliflodacin: teaching old enzymes new tricks","volume":"27","author":"Osheroff","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026071807464706600_zxag204-B10","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1128\/AAC.00786-15","article-title":"High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014","volume":"59","author":"Unemo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2026071807464706600_zxag204-B11","doi-asserted-by":"publisher","first-page":"e01479","DOI":"10.1128\/AAC.01479-19","article-title":"High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017)","volume":"63","author":"Jacobsson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2026071807464706600_zxag204-B12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3343\/alm.2024.0522","article-title":"In-vitro activities of zoliflodacin and solithromycin against Neisseria gonorrhoeae isolates from Korea","volume":"45","author":"Roh","year":"2025","journal-title":"Ann Lab Med"},{"issue":"1","key":"2026071807464706600_zxag204-B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12879-023-08938-x","article-title":"Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"24","author":"Zhong","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026071807464706600_zxag204-B14","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.ijregi.2025.100624","article-title":"High susceptibility to the novel antimicrobial zoliflodacin among Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024","volume":"15","author":"Jacobsson","year":"2025","journal-title":"IJID Reg"},{"issue":"1","key":"2026071807464706600_zxag204-B15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1128\/AAC.01211-15","article-title":"Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)","volume":"60","author":"Su","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026071807464706600_zxag204-B16","doi-asserted-by":"publisher","first-page":"e00863","DOI":"10.1128\/AAC.00863-20","article-title":"Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China, 2014 to 2018","volume":"65","author":"Le","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2026071807464706600_zxag204-B17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/antibiotics15010061","article-title":"In vitro activity of zoliflodacin against Neisseria gonorrhoeae isolates from Shanghai, China (2020-2023)","volume":"15","author":"Yao","year":"2026","journal-title":"Antibiotics"},{"issue":"8","key":"2026071807464706600_zxag204-B18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/pathogens14080831","article-title":"Susceptibility of Neisseria gonorrhoeae to zoliflodacin and quinolones in Hyogo Prefecture, Japan","volume":"14","author":"Yurube","year":"2025","journal-title":"Pathogens"},{"issue":"8","key":"2026071807464706600_zxag204-B19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00284-024-03761-2","article-title":"Efficacy of zoliflodacin, a spiropyrimidinetrione antibiotic, against gram-negative pathogens","volume":"81","author":"Oyardi","year":"2024","journal-title":"Curr Microbiol"},{"issue":"2","key":"2026071807464706600_zxag204-B20","doi-asserted-by":"publisher","first-page":"e13075","DOI":"10.1111\/hel.13075","article-title":"Evaluating the potency of zoliflodacin against Helicobacter pylori: in vitro activity and conserved GyrB target","volume":"29","author":"Liu","year":"2024","journal-title":"Helicobacter"},{"issue":"1","key":"2026071807464706600_zxag204-B21","doi-asserted-by":"publisher","first-page":"e01808","DOI":"10.1128\/AAC.01808-18","article-title":"Single-dose pharmacokinetics, excretion, and metabolism of zoliflodacin, a novel spiropyrimidinetrione antibiotic, in healthy volunteers","volume":"63","author":"O\u2019Donnell","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2026071807464706600_zxag204-B22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/cts.13487","article-title":"Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: phase I open-label randomized cross-over study in healthy subjects","volume":"16","author":"Luckey","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"19","key":"2026071807464706600_zxag204-B23","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"issue":"10524","key":"2026071807464706600_zxag204-B24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"issue":"12","key":"2026071807464706600_zxag204-B25","doi-asserted-by":"publisher","first-page":"e0129221","DOI":"10.1128\/AAC.01292-21","article-title":"Thorough QT study to evaluate the effect of zoliflodacin, a novel therapeutic for gonorrhea, on cardiac repolarization in healthy adults","volume":"65","author":"Newman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026071807464706600_zxag204-B26","doi-asserted-by":"publisher","first-page":"e70515","DOI":"10.1111\/cts.70515","article-title":"Evaluation of drug-drug interaction potential between the oral antibiotic zoliflodacin and the CYP3A4 inhibitor itraconazole: a phase 1 study in healthy participants","volume":"19","author":"Luckey","year":"2026","journal-title":"Clin Transl Sci"},{"issue":"4","key":"2026071807464706600_zxag204-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually Transmitted Infections Treatment Guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"2026071807464706600_zxag204-B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40360-016-0057-x","article-title":"Evaluation of ceftriaxone utilization in medical and emergency wards of Tikur Anbessa specialized hospital: a prospective cross-sectional study","volume":"17","author":"Sileshi","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"2026071807464706600_zxag204-B29","first-page":"773","article-title":"Factors determining the appropriateness of ceftriaxone usage at the emergency room of a university hospital in Thailand","volume":"96","author":"Phuphuakrat","year":"2013","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"2026071807464706600_zxag204-B30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/1742-6723.12037","article-title":"Inappropriate ceftriaxone use in the emergency department of a tertiary hospital in Melbourne, Australia","volume":"25","author":"Xie","year":"2013","journal-title":"Emerg Med Australas"},{"issue":"1","key":"2026071807464706600_zxag204-B31","doi-asserted-by":"publisher","first-page":"25035","DOI":"10.1038\/s41598-024-75728-z","article-title":"Inappropriate ceftriaxone utilization and predictor factors in Ethiopia: a systematic review and meta-analysis","volume":"14","author":"Tafere","year":"2024","journal-title":"Sci Rep"},{"issue":"7","key":"2026071807464706600_zxag204-B32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/antibiotics10070779","article-title":"Evaluation of the clinical use of ceftriaxone among in-patients in selected health facilities in Uganda","volume":"10","author":"Kutyabami","year":"2021","journal-title":"Antibiotics"},{"issue":"6","key":"2026071807464706600_zxag204-B33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/8755122517720293","article-title":"Appropriate use of ceftriaxone in the emergency department of a veteran\u2019s health care system","volume":"33","author":"Durham","year":"2017","journal-title":"J Pharm Technol"},{"key":"2026071807464706600_zxag204-B34","author":"Blujepa"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag204\/68689435\/zxag204.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag204\/68689435\/zxag204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:46:53Z","timestamp":1784375213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag204\/8724015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag204","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"zxag204"}}